VERA Vera Therapeutics, Inc.
8-K Current Report
Filed: March 9, 2026
Health Care
Pharmaceutical PreparationsVera Therapeutics, Inc. (VERA) 8-K current report filed with SEC EDGAR on March 9, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items1 item
- Item 5.02: Departure/Election of Directors or Officers
AI Filing Analysis8-K
Item 5.02 · Departure/Election of Directors or Officers
- • Christopher Hite appointed to Board as Class III Director effective March 5, 2026; term expires at 2027 Annual Meeting
- • Initial option grant: 24,937 shares at $38.85/share, vesting monthly over 3 years
Other Vera Therapeutics, Inc. 8-K Filings
Get deeper insights on Vera Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.